Dr. Daryl Ray Tharp Jr., MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-520-5200 |
Dr. Bradley A Brown, MD Pathology - Anatomic Pathology & Clinical Pathology Medicare: Not Enrolled in Medicare Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-581-4131 |
Bjorn Batdorf, M.D. Pathology - Anatomic Pathology Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-520-5200 |
Katharine Van Patten, M.D. Pathology - Anatomic Pathology Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Surgical Pathology Department, Robbinsdale, MN 55422 Phone: 763-581-4150 Fax: 763-581-4151 |
Tarek A. Salem, M.D. Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-520-5200 |
News Archive
Data presented for the first time at the 25th Annual Meeting and Scientific Session of the International Society for Heart and Lung Transplantation (ISHLT) show that cyclosporine inhalation solution (CyIS) significantly improves long-term survival in lung-transplant patients compared to placebo.
Many forms of vision loss stem from a common source: impaired communication between the eye and the brain. And at the root of all eye-to-brain communication are the hundreds of proteins generated by the retina's nerve cells.
Prof Emmanuelle Charpentier from the Helmholtz Centre for Infection Research in Braunschweig is one of the two recipients of the 2015 Louis-Jeantet-Prize for Medicine. The prize money of 700,000 Swiss francs is mostly attributed for the continuation of the awardees work.
Vision problems are a common and sometimes lasting consequence of head injuries—from children and teens with sports-related concussions to military personnel with combat-related traumatic brain injury (TBI).
Asterias Biotherapeutics, Inc. today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for AST-VAC1, its investigational therapy targeting acute myeloid leukemia (AML).
› Verified 4 days ago